

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|---|------------------------|---------------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | Application Number | 10/529,090 |
| | Filing Date | September 30, 2005 |
| | First Named Inventor | Kurt Lang et al. |
| | Art Unit | 1632 |
| | Examiner Name | |
| Total Number of Pages in This Submission | Attorney Docket Number | 20968 |

| ENCLOSURES (Check all that apply) | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application | Remarks | |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

REQUEST FOR CORRECTED FILING RECEIPT

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | |
|--|-------------------------|
| Firm or Individual name | Brian C. Remy |
| Signature | |
| Date | January 30, 2006 |

| CERTIFICATE OF TRANSMISSION/MAILING | |
|---|-------------------------|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. | |
| Typed or printed name | Brian C. Remy |
| Signature | |
| Date | January 30, 2006 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Receipt
IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Kurt Lang et al.

Group: 1632

Application No. 10/529,090, filed September 30, 2005
(Case Docket No. 20968)

Examiner:

For: **CONJUGATES OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4
AND POLY (ETHYLENE GLYCOL)**

REQUEST FOR CORRECTED FILING RECEIPT

Nutley, New Jersey 07110
January 30, 2006

Mail Stop: OIPE
Commissioner for Patents
Customer Service Center
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request a corrected filing receipt for the captioned case correcting the "Domestic Priority" as shown on the enclosed receipt copy.

Applicants have just received the filing receipt in Application No. 10/529,090. In reviewing the filing receipt, the Applicants noticed that the international filing date under the "Domestic Priority data as claimed by Applicant" is incorrect. The correct date is 09/25/2003 (not 09/26/2003). Therefore, please correct the "Domestic Priority data as claimed by Applicant" on the filing receipt to read as follows:


This application is a 371 of PCT/EP03/010658 09/25/2003

A marked copy of the filing receipt is enclosed herewith showing the requested correction. Also enclosed is a copy of the cover page of corresponding International

Application No. 10/529,090 .
Filed: September 30, 2005

Patent Publication No. WO 2004/028568 A1 showing the correct international filing date ("Domestic Priority data as claimed by Applicant") of September 25, 2003. Accordingly, it is respectfully requested that a new filing receipt be issued.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Brian Remy", is written over a horizontal line.

Attorney for Applicant(s)
Brian C. Remy
(Reg. No. 48176)
340 Kingsland Street
Nutley, NJ 07110
Telephone: (973) 235-6516
Telefax: (973) 235-2363

221496




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPL NO. | FILING OR 371 (c) DATE | ART UNIT | FIL FEE REC'D | ATTY. DOCKET NO | DRAWINGS | TOT CLMS | IND CLMS |
|------------|---------------------------|----------|---------------|-----------------|----------|----------|----------|
| 10/529,090 | 09/30/2005 | 1632 | 1030 | 20968 | 5 | 8 | 3 |

George W Johnston ✓
Hoffmann-La Roche Inc
340 Kingsland Street
Nutley, NJ 07110



CONFIRMATION NO. 1980

FILING RECEIPT



OC000000017847026

Date Mailed: 01/18/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Kurt Lang, Penzberg, GERMANY; ✓
Andreas Schaubmar, Penzberg, GERMANY; ✓
Ralf Schumacher, Penzberg, GERMANY; ✓

Power of Attorney: The patent practitioners associated with Customer Number 00151. ✓

Domestic Priority data as claimed by applicant

010658
This application is a 371 of PCT/EP03/10658/09/26/2003 ✓

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 02021844.2 09/27/2002 ✓

Projected Publication Date: 04/27/2006 ✓

Non-Publication Request: No

Early Publication Request: No

Title

Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol) ✓

Copy Sent to
Department PLP *Therapy*

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject

matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/028568 A1

(51) International Patent Classification⁷: **A61K 47/48**
(21) International Application Number:
PCT/EP2003/010658

(74) Agent: SCHREINER, Siegfried; Roche Diagnostics GmbH, Patent Department (TR-E), P.O. Box 11 52, 82372 Penzberg (DE).

(22) International Filing Date:
25 September 2003 (25.09.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02021844.2 27 September 2002 (27.09.2002) EP

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): F. HOFFMANN-LA ROCHE AG [CH/CH]; 124 Grenzacherstrasse, CH-4070 Basle (CH).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): LANG, Kurt [DE/DE]; Langener Strasse 10, 82377 Penzberg (DE). SCHAUBMAR, Andreas [DE/DE]; Ringstrasse 25, 81375 Muenchen (DE). SCHUMACHER, Ralf [DE/DE]; Hochfeldstrasse 78, 82377 Penzberg (DE).

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: CONJUGATES OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 AND POLY (ETHYLENE GLYCOL)



(57) Abstract: A conjugate consisting of insulin-like growth factor binding protein 4 (IGFBP-4) and one or two poly(ethylene glycol) group(s), said poly(ethylene glycol) group(s) having an overall molecular weight of from about 30 to about 40 kDa is disclosed. This conjugate is useful for the treatment of cancer.